Kazakhstan has become the first foreign country to approve the use of Russia's Sputnik M coronavirus vaccine for adolescents, the Russian Direct Investment Fund (RDIF) announced.
"RDIF announces the decision of the Ministry of Health of the Republic of Kazakhstan to approve the use of the Russian Sputnik M coronavirus vaccine for adolescents aged 12-17 in the country. Thus, Kazakhstan became the first foreign country to approve the use of Sputnik M," the report says.
Unlike some foreign producers who use the vaccine for adolescents in the same dosage as for adults, Sputnik M was adapted by the Gamaleya Research Center specifically for adolescents.
Sputnik M is a two-component preparation similar to the Sputnik V vaccine. The only difference between Sputnik M and Sputnik V is a fivefold lower concentration of adenovirus particles, which puts the adolescent immune system under less strain compared to the adult dosage.
The Russian Ministry of Health registered Sputnik M on November 24, 2021, based on clinical studies that confirmed the high safety and immunogenicity profile of this vaccine in adolescents. The studies revealed no serious adverse events associated with Sputnik M vaccination in participants. The results are consistent with data from studies and applications of Sputnik V for adult vaccination.
GSV "Russia - Islamic World"
Photo: Creative Commons
Based on materials from TASS